Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

OBJECTIVES:

I. Collect malignant, borderline malignant neoplasms, and related biological specimens from
Children's Oncology Group institutions for cases in which there is no disease-specific
biologic protocol.

II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms,
and related biological specimens from these patients.

III. Make specimens available to qualified researchers to understand the biology of cancer in
these patients.

OUTLINE:

Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future
analysis.

Inclusion Criteria:

- Meets any of the following criteria:

- Diagnosed with primary neoplasm

- Developed a second malignant neoplasm

- Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in
the International Classification of Disease for Oncology, Third Edition

- Must have biological specimens including solid tumors and leukemias available

- Solid tumors meeting the following criteria:

- Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed
(block or tissue in formalin) primary tumor AND at least 10 unstained
paraffin slides for NIH Mandated QC (tumors that have undergone central
pathology review are allowed)

- Slides for pathology review (instead of slides for QC) are required for
patients with rare tumors

- Pleural fluid or cytologic specimens meeting the following criteria:

- At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2
unstained smears)

- Slides for pathology review (instead of slides for QC) are required for
patients with rare tumors

- ALL/AML

- 3-6 mL of bone marrow aspirate and 10 mL of whole blood

- Not eligible for disease-specific biology or banking protocol